CIK 0001498382
- Non-accelerated filer
- Smaller reporting company
TuHURA Biosciences, Inc./NV
Sign in to watch- Ticker
- HURA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 990360497
- Phone
- +1 813-875-6600
- Business address
- 10500 UNIVERSITY CENTER DR., SUITE 110, TAMPA, FL, 33612
- Former names
- Kintara Therapeutics, Inc., DelMar Pharmaceuticals, Inc., Berry Only Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-06 | Dearborn Dan Chief Financial Officer | Grant or award · Options (Right to Buy) | +273,696 | 273,696 | ||
| 2025-12-12 | Dearborn Dan Chief Financial Officer | Grant or award · Options (Right to Buy) | +1,531,367 | 1,531,367 | ||
| 2024-11-12 | Dearborn Dan Chief Financial Officer | Grant or award · Options (Right to Buy) | +489,848 | 489,848 | ||
| 2024-10-18 | Dearborn Dan Chief Financial Officer | Grant or award · Options (Right to Buy) | +33,991 | 33,991 | ||
| 2024-10-18 | Dearborn Dan Chief Financial Officer | Grant or award · Options (Right to Buy) | +68,438 | 68,438 | ||
| 2024-10-18 | Dearborn Dan Chief Financial Officer | Grant or award · Options (Right to Buy) | +232,570 | 232,570 | ||
| 2024-10-18 | Dearborn Dan Chief Financial Officer | Grant or award · Options (Right to Buy) | +15,744 | 15,744 | ||
| 2024-10-18 | Dearborn Dan Chief Financial Officer | Grant or award · Options (Right to Buy) | +66,658 | 66,658 |
Page 1 of 1 · 8 trades